Table 3. DFS predictors among our cohort (n=98).
| Independents variables | Univariate predictors | Multivariate predictors | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (continuous variable) | 01.01 (0.99–1.02) | 0.260 | |||
| Gender | |||||
| Female (n=51) | Reference | ||||
| Male (n=47) | 1.05 (0.66–1.66) | 0.837 | |||
| SM status | |||||
| Positive SM (n=37) | Reference | Reference | |||
| Negative SM (n=61) | 0.64 (0.50–0.82) | <0.001 | 0.54 (0.29–0.97) | 0.041 | |
| Tumor size | |||||
| <5 cm (n=16) | Reference | Reference | |||
| ≥5 cm (n=82) | 2.03 (1.04–3.98) | 0.039 | 1.45 (0.67–3.18) | 0.349 | |
| Tumor multiplicity | |||||
| Single (n=80) | Reference | ||||
| Multiple (n=18) | 1.18 (0.89–1.57) | 0.256 | |||
| FEV% (continuous variable) | 0.80 (0.40–1.59) | 0.521 | |||
| Lesion laterality | |||||
| Rt side (n=45) | Reference | ||||
| Lt side/midline (n=53) | 0.99 (0.62–1.57) | 0.948 | |||
| Grade | |||||
| Low (NA/G1; n=50) | Reference | Reference | |||
| High (G2/G3; n=48) | 1.66 (1.04–2.63) | 0.033 | 1.56 (0.87–2.78) | 0.135 | |
| Pathology | |||||
| Soft tissue (n=44) | Reference | ||||
| Bony (n=45) | 1.12 (0.69–1.83) | 0.645 | |||
| Others (n=9) | 1.63 (0.77–3.43) | 0.199 | |||
| Complications | |||||
| No (n=81) | Reference | ||||
| Yes (n=17) | 0.94 (0.50–1.80) | 0.860 | |||
| Lung resection | |||||
| No (n=87) | Reference | ||||
| Yes (n=11) | 1.04 (0.50–2.17) | 0.923 | |||
| EBL (continuous variable) | 1.0001 (1.0001–1.001) | 0.003 | 1.0002 (0.9998–1.001) | 0.201 | |
| Adjuvant treatment | |||||
| No (n=31) | Reference | Reference | |||
| Yes (n=67) | 2.16 (1.24–3.76) | 0.007 | 1.30 (0.63–2.68) | 0.475 | |
Note: variables with P value less or equal to 0.10 in univariate analysis were involved in MVA. DFS, disease free survival; SM, safety margin; FEV, forced expiratory volume; EBL, estimated blood loss; NA, not applicable grading as fibromatosis.